瑞创生物技术

Ruichuang Biotech is a clinical-stage biopharmaceutical company based in Hangzhou, China, specializing in the development of innovative cell therapies for oncology. The company focuses on chimeric antigen receptor T-cell (CAR-T) and T-cell receptor (TCR-T) technologies to address unmet needs in hematological malignancies and solid tumors. Its lead program, RC19, is a CD19-targeted CAR-T therapy currently undergoing Phase 2 clinical trials for B-cell non-Hodgkin lymphoma. Ruichuang integrates research, clinical development, and GMP manufacturing to accelerate the delivery of cell-based medicines. The company aims to improve the safety and efficacy of immunotherapy through proprietary genetic engineering techniques.